455 related articles for article (PubMed ID: 26137204)
1. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
Chaidos A; Caputo V; Karadimitris A
Ther Adv Hematol; 2015 Jun; 6(3):128-41. PubMed ID: 26137204
[TBL] [Abstract][Full Text] [Related]
2. Bromodomains: Structure, function and pharmacology of inhibition.
Ferri E; Petosa C; McKenna CE
Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
[TBL] [Abstract][Full Text] [Related]
3. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
Taniguchi Y
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
[TBL] [Abstract][Full Text] [Related]
4. Targeting the epigenetic reader "BET" as a therapeutic strategy for cancer.
Wahi A; Manchanda N; Jain P; Jadhav HR
Bioorg Chem; 2023 Nov; 140():106833. PubMed ID: 37683545
[TBL] [Abstract][Full Text] [Related]
5. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
[TBL] [Abstract][Full Text] [Related]
6. The Functions of BET Proteins in Gene Transcription of Biology and Diseases.
Cheung KL; Kim C; Zhou MM
Front Mol Biosci; 2021; 8():728777. PubMed ID: 34540900
[TBL] [Abstract][Full Text] [Related]
7. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
9. Bromodomain inhibitors and cancer therapy: From structures to applications.
Pérez-Salvia M; Esteller M
Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
[TBL] [Abstract][Full Text] [Related]
10. The Bromodomain: A New Target in Emerging Epigenetic Medicine.
Smith SG; Zhou MM
ACS Chem Biol; 2016 Mar; 11(3):598-608. PubMed ID: 26596782
[TBL] [Abstract][Full Text] [Related]
11. The making of I-BET762, a BET bromodomain inhibitor now in clinical development.
Zhao Y; Yang CY; Wang S
J Med Chem; 2013 Oct; 56(19):7498-500. PubMed ID: 24107192
[TBL] [Abstract][Full Text] [Related]
12. Targeting bromodomains: epigenetic readers of lysine acetylation.
Filippakopoulos P; Knapp S
Nat Rev Drug Discov; 2014 May; 13(5):337-56. PubMed ID: 24751816
[TBL] [Abstract][Full Text] [Related]
13. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Alqahtani A; Choucair K; Ashraf M; Hammouda DM; Alloghbi A; Khan T; Senzer N; Nemunaitis J
Future Sci OA; 2019 Mar; 5(3):FSO372. PubMed ID: 30906568
[TBL] [Abstract][Full Text] [Related]
14. Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors.
Bechter O; Schöffski P
Pharmacol Ther; 2020 Apr; 208():107479. PubMed ID: 31931101
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain Protein Inhibitors Reorganize the Chromatin of Synovial Fibroblasts.
Krošel M; Moser L; Houtman M; Friščić J; Tomšič M; Distler O; Hoffmann MH; Ospelt C; Klein K
Cells; 2023 Apr; 12(8):. PubMed ID: 37190058
[TBL] [Abstract][Full Text] [Related]
16. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
Chaidos A; Caputo V; Gouvedenou K; Liu B; Marigo I; Chaudhry MS; Rotolo A; Tough DF; Smithers NN; Bassil AK; Chapman TD; Harker NR; Barbash O; Tummino P; Al-Mahdi N; Haynes AC; Cutler L; Le B; Rahemtulla A; Roberts I; Kleijnen M; Witherington JJ; Parr NJ; Prinjha RK; Karadimitris A
Blood; 2014 Jan; 123(5):697-705. PubMed ID: 24335499
[TBL] [Abstract][Full Text] [Related]
17. BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects.
Abedin SM; Boddy CS; Munshi HG
Onco Targets Ther; 2016; 9():5943-5953. PubMed ID: 27729803
[TBL] [Abstract][Full Text] [Related]
18. Targeting BET bromodomain proteins in cancer: The example of lymphomas.
Spriano F; Stathis A; Bertoni F
Pharmacol Ther; 2020 Nov; 215():107631. PubMed ID: 32693114
[TBL] [Abstract][Full Text] [Related]
19. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
20. Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases.
Padmanabhan B; Mathur S; Manjula R; Tripathi S
J Biosci; 2016 Jun; 41(2):295-311. PubMed ID: 27240990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
